B7.1 Is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells

Journal of Immunology

Volumn 161, Issue 10, 1998, Pages 5268-5275

  Fields, Patrick E ^a   Finch, Rosalynde J ^b   Gray, Gary S ^c   Zollner, Richard ^c   Thomas, Jenifer L ^c   Sturmhoefel, Knut ^c   Lee, Kwan ^c   Wolf, Stanley ^c   Gajewski, Thomas F ^a   Fitch, Frank W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD80; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; HOMEODOMAIN PROTEINS; HUMANS; LYMPHOCYTE ACTIVATION; MAST-CELL SARCOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032533482     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
2. L. Immunity 3:87.
3. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 356:607.
4. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, and P. S. Linsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand, B7/BB1. J. Exp. Med. 177:165.
5. Stack, R. M., D. J. Lenschow, G. S. Gray, J. A. Bluestone, and F. W. Fitch. 1994. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J. Immunol 152:5723.
6. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
7. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
8. van Dijk, A. M. C., H. G. Otten, S. M. Vercauteren, F. L. Kessler, M. de Boer. L. F. Verdonck, and G. C. de Gast. 1996. Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. Eur. J. Immunol. 26:2275.
9. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
10. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156: 2909.
11. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
12. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
13. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:97.
14. Natesan, M., Z. Razi-Wolf, and H. Reiser. 1996. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J. Immunol. 156:2783.
15. Croft, M., L. M. Bradley, and S. L. Swain. 1994. Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen presenting cell types including B cells. J. Immunol. 152:2675.
16. Dubey, C., M. Croft, and S. L. Swain. 1996. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol. 157:3280.
17. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335:271.
18. Shinkai, Y., G. Rathbun, K.-P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. M. Stall, et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855.
19. Dunn, Y. B., and M. J. Potter. 1957. A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18:587.
20. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
21. Freeman, G. J., F. Boriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, G. Laszlo, et al. 1993. Murine B7-2, an alternative CTLA-4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J. Exp. Med. 178:2185.
22. Nelson, B. H., J. D. Lord, and P. D. Greenberg. 1994. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate th e signal for T cell proliferation. Nature 369:333.
23. Gunning, P., J. Leavitt, G. Muscat, S. Y. Ng, and L. Kedes. 1987. A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84:4831.
24. Davidson, W. F., and C. R. Parish. 1975. A procedure for removing red cells and dead cells from lymphoid cells. J. Immunol. Methods 7:291.
25. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
26. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
27. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445.
28. Linsley, P. S., J. L. Green, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
29. Eck, S. C., D. Chang, A. D. Wells, and L. A. Turka. 1997. Differential down-regulation of CD28 by B7-1 and B7-2 engagement. Transplantation 64:1497.
30. Kariv, I., A. Truneh, and R. W. Sweet. 1996. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. J. Immunol. 157:29.
31. Anderson, D. E., L. J. Ausubel, J. Krieger, P. Hollsburg, G. J. Freeman, and D. A. Hafler. 1997. Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones. J. Immunol. 159:1669.
32. -) to TCR/CD8 signaling in response to antigen. J. Immunol. 160:3236.
33. + T cells. Science 271:1276.
34. + T cells. J. Exp. Med. 186:757.